Acute ACAT1/SOAT1 Blockade Increases MAM Cholesterol and Strengthens ER-Mitochondria Connectivity.

Area of Science:

• Cell Biology
• Neuroscience
• Biochemistry

Background:

• Cholesterol metabolism disruptions are linked to neurodegenerative diseases like Alzheimer's disease (AD).
• Acyl-CoA:cholesterol acyltransferase 1 (ACAT1/SOAT1) inhibition shows therapeutic potential in AD mouse models.
• The molecular mechanisms linking ACAT1/SOAT1 blockade to autophagy and lysosomal benefits are unclear.

Purpose of the Study:

• To elucidate the molecular mechanisms by which ACAT1/SOAT1 inhibition impacts cellular structures.
• To investigate the role of cholesterol accumulation at the mitochondria-associated ER membrane (MAM) in AD.
• To determine how ACAT1/SOAT1 inhibition affects ER-mitochondria contact sites.

Main Methods:

• Biochemical fractionation to analyze cholesterol localization and enzyme enrichment.
• Proteomics analysis of MAM to identify changes upon ACAT1/SOAT1 inhibition.
• Confocal and electron microscopy to visualize and quantify ER-mitochondria contact sites.

Main Results:

• Cholesterol accumulates at the MAM, leading to ACAT1/SOAT1 enrichment in this domain.
• ACAT1/SOAT1 inhibition strengthens the ER-mitochondria connection.
• Inhibition increases the number and physical proximity of ER-mitochondria contact sites.

Conclusions:

• Cholesterol buildup at the MAM is a key consequence of ACAT1/SOAT1 activity.
• ACAT1/SOAT1 inhibition alters inter-organellar contact sites by modulating local cholesterol levels.
• This study suggests cholesterol accumulation at the MAM is central to the therapeutic benefits of ACAT1/SOAT1 inhibition in AD.